Catheter ablation

Intervention1 paper4 findingsMeSH D017115

  • Humans1

Outcomes

1

Modified Rankin Scale

upin humans1Low certainty

1 study
  1. Catheter ablation improves modified Rankin Scale in humans (aOR 0.31 (95% CI 0.19-0.51)).

    Humanspatients with AF and a history of ischemic strokemedian follow-up 3.0 yearsn = 250

    Early ablation lowers cardiac risks in stroke patients with AF · Neurology · 1 Oct 2026

Modified Rankin Scale →

Associations

3

Cognitive impairment

downin humans1Low certainty

1 study
  1. Catheter ablation lowers the risk of cognitive impairment in humans (aOR 0.42 (95% CI 0.24-0.72)).

    Humanspatients with AF and a history of ischemic strokemedian follow-up 3.0 yearsn = 250

    Early ablation lowers cardiac risks in stroke patients with AF · Neurology · 1 Oct 2026

Cardiovascular rehospitalization

downin humans1Low certainty

1 study
  1. Catheter ablation lowers the risk of cardiovascular rehospitalization in humans (absolute difference 11.98% (95% CI 2.26%-21.44%)).

    Humanspatients with AF and a history of ischemic stroke36 monthsn = 431

    Early ablation lowers cardiac risks in stroke patients with AF · Neurology · 1 Oct 2026

Major adverse cardiovascular events

downin humans1Low certainty

1 study
  1. Catheter ablation lowers the risk of major adverse cardiovascular events in humans (ARR 11.17% (95% CI 5.81%-17.36%)).

    Humanspatients with AF and a history of ischemic stroke36 monthsn = 431

    Early ablation lowers cardiac risks in stroke patients with AF · Neurology · 1 Oct 2026

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 11
NeurologyHumans

Early ablation lowers cardiac risks in stroke patients with AF

At 36 months, early ablation yielded a 1.54-month gain in event-free survival and an 11.17% absolute risk reduction in major adverse cardiovascular…At 36 months, early ablation yielded a 1.54-month gain in event-free survival and an 11.17% absolute risk reduction in major adverse cardiovascular events versus medical therapy.